Cargando…

Successful immunomodulation in kidney transplant recipients with cytokine release syndrome after coronavirus disease

INTRODUCTION: Patients with coronavirus disease, especially solid organ transplant recipients, are more susceptible to developing cytokine release syndrome than those with other viral infections. However, currently, treatment methods for such patients have not been established. Here, we describe two...

Descripción completa

Detalles Bibliográficos
Autores principales: Takamoto, Daiji, Sasaki, Hajime, Kataoka, Hiroshi, Kodama, Fumihiro, Higuchi, Haruka, Hirano, Tetsuo, Takada, Yusuke, Harada, Shigeru, Harada, Hiroshi, Tanaka, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350256/
https://www.ncbi.nlm.nih.gov/pubmed/35942072
http://dx.doi.org/10.1002/iju5.12492
Descripción
Sumario:INTRODUCTION: Patients with coronavirus disease, especially solid organ transplant recipients, are more susceptible to developing cytokine release syndrome than those with other viral infections. However, currently, treatment methods for such patients have not been established. Here, we describe two cases of successful immunomodulation in Japanese kidney transplant recipients with cytokine release syndrome following coronavirus disease. CASE PRESENTATION: Two patients who had been receiving long‐term immunosuppressant therapy developed coronavirus disease‐associated pneumonia caused by cytokine release syndrome, following immunosuppressant dosage reduction. However, they recovered immediately after administration of tocilizumab with or without dexamethasone. CONCLUSION: The immunosuppressant dosage should be reduced to restore host immunity; however, immunomodulation should be considered in cases of suspected cytokine release syndrome.